Labgenomics Co

Labgenomics Co Net Margin

The Net Profit Margin of Labgenomics Co (084650.KQ) as of Nov 7, 2026 is -73.02 %. In the previous year, Net Profit Margin was -27.70 % — a change of 163.58% (lower).

Net Margin

-73.02 %

YoY

163.58%

Last updated:

Net Profit Margin of Labgenomics Co is 2025 -73.02 % . Net Profit Margin of Labgenomics Co was 2024 -27.70 % . It decreases by 163.58% lower compared to the previous year.

Labgenomics Co's net margin stands at -73.0%, down from 41.4% several years earlier.

The Labgenomics Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-14.43 KRW
Jan 1, 2019
2.90 KRW
Jan 1, 2020
35.79 KRW
Jan 1, 2021
41.43 KRW
Jan 1, 2022
33.43 KRW
Jan 1, 2023
-6.58 KRW
Jan 1, 2024
-27.70 KRW
Jan 1, 2025
-73.02 KRW
The Labgenomics Co Net Margin history
YEARNet MarginYoY
-73.02 %+163.58%
-27.70 %+321.27%
-6.58 %-119.67%
33.43 %-19.31%
41.43 %+15.74%
35.79 %+1,133.86%
2.90 %-120.11%
-14.43 %+4.14%
-13.85 %-560.64%
3.01 %-56.38%
6.89 %-33.90%
10.43 %+13,947.25%
0.07 %+16.29%
0.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Net Profit Margin of Labgenomics Co is -73.02 % in 2025.

Net Profit Margin of Labgenomics Co changed from -27.70 % to -73.02 %, representing a 163.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Labgenomics Co

All Key Metrics — Labgenomics Co